Pharmaceutical composition comprising phytocannabinoid cannabi divaline (CBDV) and cannabidiol (CBD)

The present invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabi divaline (CBDV) and cannabidiol (CBD). This composition is particularly safe and effective for use in the treatment of neurological conditions characterized by central nervous system hyperexcitation, convulsions or seizures such as occur in epilepsy. CBDV and CBD are preferably present with at least one non-cannabinoid component of cannabis, such as one or more terpenes, or terpene fractions. More specifically, the composition further comprises one or more cannabichromene-type compounds, in particular cannabichromenpropyl variants (CBCV) and / or cannabichromene (CBC). More specifically, the composition is typically considered to be present in significant amounts in cannabis chemotypes bred to contain significant amounts of CBDV and / or CBD, particularly tetrahydrocannabinol (THC). ) And other cannabinoids including tetrahydrocannabinavalin (THCV) or substantially free of this. [Selection figure] None